Literature DB >> 7308282

Pharmacokinetic concepts - drug binding, apparent volume of distribution and clearance.

M Gibaldi, J R Koup.   

Abstract

Blood flow rate-limited physiological pharmacokinetic models have been used to examine the relationship between apparent volume of distribution and clearance or, more specifically between drug binding in blood, eliminating regions or noneliminating regions and clearance. The influence of binding on drug elimination depends on the driving force concentration in the eliminating region. In most instances this is likely to be free drug concentration in the region. Under these conditions, the results indicate that apparent volume of distribution and drug clearance from the blood should be treated as independent pharmacokinetic variables. Volume of distribution per se has no effect on clearance or on average steady-state blood levels. Drug binding in nonvascular regions(i.e. tissue binding) seems to be of limited importance except as a determinant of half-life. Although changes in tissue binding will affect partition coefficient and apparent volume of distribution, such changes will have no effect on average steady-state blood levels of either total or free drug.

Mesh:

Substances:

Year:  1981        PMID: 7308282     DOI: 10.1007/bf00618781

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  16 in total

1.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  Animal scale-up.

Authors:  R L Dedrick
Journal:  J Pharmacokinet Biopharm       Date:  1973-10

3.  Comparative pharmacokinetics of coumarin anticoagulants XXXII: Interindividual differences in binding of warfarin and dicumarol in rat liver and implications for physiological pharmacokinetic modeling.

Authors:  G Levy; C M Lai; A Yacobi
Journal:  J Pharm Sci       Date:  1978-02       Impact factor: 3.534

4.  Effect of quinidine on plasma concentration and renal clearance of digoxin. A clinically important drug interaction.

Authors:  R Dahlqvist; G Ejvinsson; K Schenck-Gustafsson
Journal:  Br J Clin Pharmacol       Date:  1980-04       Impact factor: 4.335

5.  Numerical integration simulation programs for the microcomputer.

Authors:  J R Koup; D R Benjamin
Journal:  Ther Drug Monit       Date:  1980       Impact factor: 3.681

6.  Further observations on relationships between antipyrine half-life, clearance and volume of distribution: an appraisal of alternative kinetic parameters used to assess the elimination of antipyrine.

Authors:  L G Sultatos; B H Dvorchik; E S Vesell; D G Shand; R A Branch
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

7.  Effect of plasma protein and tissue binding on the biologic half-life of drugs.

Authors:  M Gibaldi; G Levy; P J McNamara
Journal:  Clin Pharmacol Ther       Date:  1978-07       Impact factor: 6.875

8.  Species similarities in pharmacokinetics.

Authors:  R L Dedrick; K B Bischoff
Journal:  Fed Proc       Date:  1980-01

9.  Apparent quinidine-induced digoxin toxicity after withdrawal of pentobarbital: a case of sequential drug interactions.

Authors:  D J Chapron; D Mumford; G I Pitegoff
Journal:  Arch Intern Med       Date:  1979-03

Review 10.  The construction of a pharmacokinetic model for the disposition of polychlorinated biphenyls in the rat.

Authors:  M W Anderson; T E Eling; R J Lutz; R L Dedrick; H B Matthews
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

View more
  28 in total

Review 1.  Age-related changes in protein binding of drugs: implications for therapy.

Authors:  M K Grandison; F D Boudinot
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

Review 2.  Nonlinear pharmacokinetics: clinical Implications.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

3.  The effect of age on serum concentrations of albumin and alpha 1-acid glycoprotein.

Authors:  B T Veering; A G Burm; J H Souverijn; J M Serree; J Spierdijk
Journal:  Br J Clin Pharmacol       Date:  1990-02       Impact factor: 4.335

Review 4.  Measurement and analysis of unbound drug concentrations.

Authors:  J D Wright; F D Boudinot; M R Ujhelyi
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

5.  Effect of saturable serum protein binding on the pharmacokinetics of unbound cefonicid in humans.

Authors:  M N Dudley; W C Shyu; C H Nightingale; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

6.  Plasma protein binding of furosemide in the elderly.

Authors:  G M Pacifici; A Viani; H U Schulz; H J Frercks
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

7.  The effect of beta-adrenoceptor antagonists on the pharmacokinetics and pharmacodynamics of warfarin after a single dose.

Authors:  N D Bax; M S Lennard; G T Tucker; H F Woods; N R Porter; R G Malia; F E Preston
Journal:  Br J Clin Pharmacol       Date:  1984-05       Impact factor: 4.335

8.  Relationships between body composition parameters and fluorouracil pharmacokinetics.

Authors:  Milena Gusella; Sivia Toso; Eros Ferrazzi; Mariano Ferrari; Roberto Padrini
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

9.  Influence of obesity on sulfonamide disposition in Zucker rats.

Authors:  S Kaul; W A Ritschel
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1988 Oct-Dec       Impact factor: 2.441

10.  The metabolic disposition of flucloxacillin in patients with impaired kidney function.

Authors:  H H Thijssen; J Wolters
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.